Clozapine-Induced Obsessive Compulsive Symptoms;Plasma Dabigatran Activity One Week after Discontinuation in a Patient with Normal Renal Function;Antabuse Reaction Due to Occupational Solvent Exposure;Withdrawal Symptoms with Dronabinol;Pseudolithiasis Due to Ceftriaxone

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers.